We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00774488
First Posted: October 17, 2008
Last Update Posted: October 17, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
German Research Foundation
Information provided by:
German Institute of Human Nutrition
October 16, 2008
October 17, 2008
October 17, 2008
January 2006
July 2007   (Final data collection date for primary outcome measure)
Changes in gene expression of subcutaneous adipose tissue with microarray analysis [ Time Frame: 3 years ]
Same as current
No Changes Posted
Analysis of inflammatory marker (blood levels and gene expression), Activity of 11beta HSD and 11-beta HSD mRNA in adipose tissue, etc. [ Time Frame: 3 years ]
Same as current
Not Provided
Not Provided
 
Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue
Not Provided
This clinical, randomized, cross-over study in obese healthy subjects aimed to analyse the acute effects of the incretin hormon Glucose Dependent Insulinotropic Polypeptide (GIP) on metabolic parameters and gene expression in subcutaneous adipose tissue.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
  • Metabolic Syndrome
  • Obesity
  • Insulin Sensitivity
Other: Glucose dependent insulinotropic polypeptide (GIP)
GIP-Infusions for 4 h in a postprandial concentration
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
July 2007
July 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI > 28
  • Healthy subjects
  • Normal glucose tolerance

Exclusion Criteria:

  • Diabetes,IFG, IGT
  • Chronical-inflammatory diseases
  • Hb < 12g/dl
  • Elevation in liver enzymes or creatinin concentrations
  • Great weight changes within last 12 months
  • Any cancer diagnosis in last 10 years
Sexes Eligible for Study: Male
18 Years to 70 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00774488
GIP-Genexpression Study
Yes
Not Provided
Not Provided
AFH. Pfeiffer, German Institute of Human Nutrition
German Institute of Human Nutrition
German Research Foundation
Not Provided
German Institute of Human Nutrition
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP